October 14, 2013
2 min read

Oral tyrosine kinase inhibitor shows promising early results in AMD patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Oral pazopanib was well tolerated and may have improved visual acuity and central retinal lesion thickness in patients with neovascular age-related macular degeneration, according to a small study.

The analysis comprised data from two studies: a 14-day phase 1 placebo-controlled study with 72 healthy subjects and a 28-day phase 2a open-label study with 15 patients who had subfoveal choroidal neovascularization secondary to AMD.

The AMD patients received oral pazopanib 15-mg tablets once daily for 28 days. Healthy subjects received single or repeated oral pazopanib 5-, 10-, 20- or 30-mg tablets or placebo once daily for 14 days.

Patients were examined at baseline and weekly during treatment.

Administration of a 15-mg dose for 28 days yielded a mean eight-letter gain in best corrected visual acuity, a reduction in central retinal thickness of 50.28 µm and a reduction in central retinal lesion thickness of 50.94 µm in nine AMD patients who did not undergo rescue therapy.

Six AMD patients received intravitreal injection of anti-VEGF agents; all six patients had the high-risk CFH Y402H CC genotype for AMD.

Mild to moderate ocular adverse events were reported by seven of 15 patients in the AMD group. The most common non-ocular adverse events were intermittent headache in two patients and upper respiratory tract infection in two patients.

Pazopanib was well tolerated in the healthy subjects and patients with AMD.

Disclosure: See the study for a full list of all authors’ relevant financial disclosures.